SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : A Biotech Bash - Recs and Wrecks
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (20)8/25/1997 10:59:00 PM
From: r. peter Dale   of 171
 
Henry:

I'm can't begin to respond to all of your posts but I'm confused by a point made in this post in particular. You must not have read my post #16 carefully. I am quite familiar the molecular structure, signaling properties, and domain specificity of SH2/SH3. This was clearly deducible from my journal club reference. I am also well aware of the nature of Ariad's focus.

Let me lay out the question for you:

You stated:
...LGND has extablished itself as the leader in transcription factors for non-polypeptide hormones, an area not really targeted by ARIA.

I reasoned:
Ariad studies SH2/SH3 domains, Henry is claiming that non-polypeptide hormones are not really targeted by Ariad, therefore he most know something about the SH2/SH3 structure of non-polypetide hormones.

Therefore, I asked:
...are you claiming that no non-polypeptide hormones have SH2/SH3 domains?

If they do, then Ariad has the capacity to target them even though their curent focus is elsewhere.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News